Resource Logo
NLM AIDSLINE

Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.




 

Antivir Ther. 1998;3 Suppl 4:55-6. Unique Identifier : AIDSLINE

Human immunodeficiency virus (HIV)-infected, active intravenous drug users received once-daily therapy consisting of a combination of didanosine (2',3'-dideoxyinosine or DDI), lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine or 3TC] and nevirapine. Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects.

CLINICAL TRIAL JOURNAL ARTICLE Adult CD4 Lymphocyte Count Didanosine/*ADMINISTRATION & DOSAGE Drug Therapy, Combination Female Human HIV Infections/COMPLICATIONS/*DRUG THERAPY *HIV-1 Lamivudine/*ADMINISTRATION & DOSAGE Male Methadone/THERAPEUTIC USE Nevirapine/*ADMINISTRATION & DOSAGE Pilot Projects Prospective Studies Substance Abuse, Intravenous/*COMPLICATIONS/DRUG THERAPY Viral Load



 




Information in this article was accurate in June 30, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.